DoJ closes Bristol-Myers Squibb FCPA investigation

Pharmaceutical company Bristol-Myers Squibb, which on 5 October paid US$14 million to settle US Securities and Exchange Commission charges that its Chinese joint venture bribed health-care providers, has been notified that the US Department of Justice has declined to bring its own case.

Unlock unlimited access to all Global Investigations Review content